

COPD und kardiovaskuläre Komorbiditäten: Interaktionen zwischen Lunge und Herz

P. Alter, C. F. Vogelmeier, R. A. Jörres

Literatur:

1. Vanfleteren LEGW et al. Clusters of Comorbidities Based on Validated Objective Measurements and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2013; 187: 728–735
2. Hillas G et al. Managing comorbidities in COPD. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 95–109
3. Gershon AS et al. Quantifying comorbidity in individuals with COPD: a population study. *Eur Respir J* 2015; 45: 51–59
4. Kahnert K et al.; COSYCONET consortium. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. *PLoS One* 2017; 12: e0177501
5. Greulich T et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. *Respir Med* 2017; 132: 132–138
6. Kahnert K et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. *Respir Res* 2018; 19: 110
7. Mantoani LC et al. Physical activity in patients with COPD: the impact of comorbidities. *Expert Rev Respir Med* 2017; 11: 685–698
8. Franssen FM et al. Personalized medicine for patients with COPD: where are we? *Int J Chron Obstruct Pulmon Dis* 2019; 14: 1465–1484
9. Kahnert K et al.; COSYCONET study group. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. *Respir Res* 2017; 18: 14
10. Kahnert K et al. The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET. *Respir Res* 2020; 21: 28
11. Vogelmeier CF et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med* 2017; 195: 557–582
12. Kahnert K et al.; COSYCONET Study-Group. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. *Respir Med* 2020; 172: 106117
13. Alter P et al. Update in Chronic Obstructive Pulmonary Disease 2019. *Am J Respir Crit Care Med* 2020; 202: 348–355
14. Krishnan JA et al. Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. *Ann Am Thorac Soc* 2019; 16: 1143–1150
15. Alter P et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 2163–2172
16. Hawkins NM et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Eur J Heart Fail* 2009; 11: 292–298
17. Fisher KA et al. Impact of COPD on the Mortality and Treatment of Patients Hospitalized With Acute Decompensated Heart Failure: The Worcester Heart Failure Study. *Chest* 2015; 147: 637–645
18. Iversen KK et al.; ECHOS Lung Function Study Group. The prognostic importance of lung function in patients admitted with heart failure. *Eur J Heart Fail* 2010; 12: 685–691
19. Andreas S et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. *Chest* 2005; 128: 3618–3624

20. Dransfield MT et al.; BLOCK COPD Trial Group. Metoprolol for the Prevention of Acute Exacerbations of COPD. *N Engl J Med* 2019; 381: 2304–2314
21. Omlor AJ et al.; German COSYCONET Cohort. Time-updated resting heart rate predicts mortality in patients with COPD. *Clin Res Cardiol* 2020; 109: 776–786
22. Jensen MT et al. Resting heart rate is a predictor of mortality in COPD. *Eur Respir J* 2013; 42: 341–349.
23. Su T-H et al. β -blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. *PLoS One* 2019; 14: e0213187
24. Short PM et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. *BMJ* 2011; 342: d2549
25. Calverley PMA et al.; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH Study results. *Thorax* 2010; 65: 719–725
26. Vestbo J et al.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet* 2016; 387: 1817–1826.
27. Andreas S et al. Effect of long-acting β_2 -agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. *Pulm Pharmacol Ther* 2018; 52: 1–6
28. Andreas S et al. A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 1955–1965
29. Andreas S et al. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 1935–1944
30. Alter P et al. COPD und kardiovaskuläre Komorbiditäten. *Pneumo News* 2018; 10: 27–31
31. Watz H et al. Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD: Role of Hyperinflation. *Chest* 2010; 138: 32–38
32. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med* 2010; 362: 217–227
33. Karch A et al.; COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. *Respir Med* 2016; 114: 27–37
34. Alter P et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD. *Int J Cardiol* 2018; 261: 172–178
35. Alter P et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. *Respir Med* 2018; 137: 14–22
36. Alter P et al. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. *Respir Res* 2019; 20: 61
37. Stone IS et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016; 193: 717–726
38. Hohlfeld JM et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. *Lancet Respir Med* 2018; 6: 368–378
39. Vogel-Claussen J et al. Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial. *Am J Respir Crit Care Med* 2019; 199: 1086–1096
40. Kühl K et al. Mental disorders and quality of life in COPD patients and their spouses. *Int J Chron Obstruct Pulmon Dis* 2008; 3: 727–736
41. von Siemens SM et al.; COSYCONET study group. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. *Respir Res* 2019; 20: 30